The number of new or newly enlarged hyperintense lesions on T2-weighted magnetic resonance imaging ( MRI ) over a period of 96 weeks was lower with daclizumab HYP than with interferon beta-1a ( 4.3 vs. 9.4 ; 54 % lower number of lesions with daclizumab HYP ; P < 0.001 ) .